Menu
Not yet recruiting NCT07279220

Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture

No phase Interventional Femoral Artery Puncture Vascular Closure Device Hemostasis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vascular Closure Device Manufactured by Shanghai Bomaian Medical Technology Co., Ltd., MynxGrip Vascular Closure Device Manufactured by Cordis US Corp.
Who it may be relevant to
Registry conditions: Femoral Artery Puncture, Vascular Closure Device, Hemostasis. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture

Overview

The purpose of this study is to verify the safety and effectiveness of the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture.

Interventions

  • Device Vascular Closure Device Manufactured by Shanghai Bomaian Medical Technology Co., Ltd.
    The test group will use the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture
  • Device MynxGrip Vascular Closure Device Manufactured by Cordis US Corp
    The control group will use MynxGrip Vascular Closure Device Manufactured by Cordis US Corp for femoral artery hemostasis in patients of femoral artery puncture

Primary outcome measures

  • Device Success Rate [Time frame: Intra-procedure]
Secondary outcome measures (3)
  • Time to Hemostasis [Time frame: Time from completion of femoral artery puncture site closure operation using the vascular closure device system to achievement of hemostasis, which will be assessed up to 1 day]
  • Time to Ambulation [Time frame: Time from completion of femoral artery puncture site closure operation using the vascular closure device system to the patient's ability to ambulate at least 6 meters, which will be assessed up to 30 days]
  • Time to Hospital Discharge [Time frame: Time from completion of femoral artery puncture site closure operation using the vascular closure device system to Hospital discharge determined by physician, which will be assessed up to 30 days]

Eligibility criteria

Inclusion criteria

  • Age 18\~80, male or non-pregnant female;
  • Subjects undergoing interventional diagnostic or therapeutic procedures via femoral artery puncture;
  • Subjects using 5F to 8F sheaths during the procedure (Note: Subjects using 5F-7F sheaths will enter the main randomized controlled cohort, while subjects using 8F sheaths will directly enter the single-arm observational cohort);
  • Subjects or their legally authorized representatives can understand the purpose of the trial, voluntarily participate in the trial and sign informed consent form, and be able and willing to comply with follow-ups and related procedures.

Exclusion criteria

  • Subjects with femoral artery occlusion or visually estimated lumen diameter <5mm;
  • Subjects with prior surgical procedures, percutaneous transluminal angioplasty (PTA), stent placement, or vascular grafts at the access site;
  • Subjects with visible calcification at the access site, clinically significant peripheral vascular disease (requiring intervention), or stent implantation ≤1cm from the puncture site;
  • Subjects whose puncture site is above the lowest edge of the inferior epigastric artery and/or above the inguinal ligament as identified by skeletal markers;
  • Subjects with posterior wall vascular puncture or multiple femoral artery punctures due to difficulty in obtaining vascular access;
  • Patients with pathological obesity (BMI >40 kg/m²);
  • Subjects with pre-existing access site complications (hematoma, pseudoaneurysm, arteriovenous fistula, dissection, etc) or any procedure-related complications that may affect recovery, ambulation, or discharge timing;
  • Subjects with acute ST-segment elevation myocardial infarction within 48 hours prior to the procedure;
  • Subjects with uncontrolled hypertension during closure (Systolic BP >180 mmHg or Diastolic BP >110 mmHg);
  • Subjects who are known to be contraindicated or allergic to iodine-containing contrast agents or polyethylene glycol materials;
  • Subjects with severe thrombocytopenia (Platelet count <30×10⁹/L), hemophilia, von Willebrand disease, or severe anemia (Hemoglobin <10 g/dL, Hematocrit <30%);
  • International normalized ratio (INR) >1.5;
  • Subjects with systemic infection or skin infection at the puncture site, or planned indwelling sheath;
  • Subjects unable to ambulate 6 meters without assistance;
  • Pregnant or lactating women;
  • Subjects currently participating in other drug/device clinical trials;
  • Other subjects deemed ineligible for this clinical trial by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The Second Affiliated Hospital of Army Medical University (PLA) — Chongqing

Identifiers

NCT: NCT07279220 · BMA-202501

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗